Abstract:Background: Aspirin can induce small bowel injury. There is no proven treatment of aspirin enteropathy other than withdrawal. Recently, a novel aspirin associated with phosphatidylcholine(PC) is designed to be gastric protective due to hydrophobic property of PC. Lysophosphatidic acid (LPA), a metabolite from PC and mucin were found to play roles in integrity of gastrointestinal tract epithelium. This study hypothesized that PC-aspirin would reduce aspirin-induced small bowel injury. Methods: Sprague-Dawley rats were intra-duodenally administrated with either PC-aspirin (100mg, n=12-14), Plain aspirin (100mg, n=12-14) or vehicle (1ml 2%methtcellylulose, n=12), and euthanized after 90 minutes. Small bowel injury was assessed by lesion area, vascular permeability (i.v. 1% Evan's blue solution), intestinal hemoglobin concentration and histological change (H&E stained slides were scored with a scoring system). Apoptotic index was estimated with western blot and TUNEL staining (apoptotic cell in 5 villi would be counted). The expressions of lysophosphatidic acid receptor 2 (LPA2), MUC2 the mainly expressed secretory mucin in intestine, and TLR4, MyD88, NF-κΒp50 were test with Western blot or real-time PCR. Mucins were stained with Periodic Acid Schiff (PAS). Prostaglandin E2 (PGE2) concentration were detect with ELISA. Results: Comparing to plain aspirin-treated rats, PC-aspirin caused fewer injuries in the small bowel as assessed in: lesion area (4.82±1.61mm2 vs 196.00±84.89mm2 P=0.003), vascular permeability (42.81±7.69ug/ml vs 74.73±18.61ug/ml P=0.003), intestinal hemoglobin concentration (66.67±16.81ng/ml vs 91.83±14.80ng/ml P=0.020) and histological change (2.12±0.56 vs 3.06±1.07 P=0.044)(Figure 1). Also a decreased apoptotic index was found in PC-aspirin group (16.43±4.28 vs 38.71±5.59 P<0.001 for TUNEL, 0.49±0.14 vs 1.06±0.33 P=0.007 for cleaved caspase-3, 0.81±0.29 vs 1.40±0.56 P=0.043 for cleaved caspase-7, Figure 1). Immunohistochemical staining and western blot (0.21±0.06 vs 0.14±0.06 P=0.044 for PCaspirin vs Plain aspirin) showed that LPA2-positive cells were strongly expressed in surfacelining of small bowel mucosa in the control and PC-aspirin groups but not in the plain aspirin group (Figure 2). Moreover, PAS staining reveals a thicker mucin layer in PC-aspirin rats, with a higher MUC2 mRNA level than plain aspirin rats (1.70±0.75 vs 0.98±0.45 P= 0.039)(Figure 2). The tissue expressions of TLR4, MyD88, NF-κΒp50 and COX-2 were increased while PGE2was decreased in both plain aspirin and PC-aspirin groups. Conclusion: PC-aspirin significantly decreased aspirin induced small bowel injury, this effect may associated with (1) increased LPA2 expression, which protect mucosa from apoptotic damages, and (2) increased MUC2 mRNA expression and decreased mucin layer consumption caused by aspirin, which help to suppress bacterial invasion.

The effect of an acute aspirin challenge on intestinal permeability in healthy adults with and without prophylactic probiotic consumption: a double-blind, placebo-controlled, randomized trial

The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial

Lactobacillus complex capsules ameliorate aspirin-related small intestinal mucosal injury: a prospective, randomized, controlled clinical trial

Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin

Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats.

IDDF2019-ABS-0188 Gut Microbiota Modulates the Chemopreventive Efficacy of Aspirin on Colorectal Cancer Through Impact on Aspirin Bioavailability

Exploratory plasma proteomic analysis in a randomized crossover trial of aspirin among healthy men and women

AG1®, a Novel Synbiotic, Maintains Gut Barrier Function following Inflammatory Challenge in a Caco-2/THP1-BlueTM Co-Culture Model

Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage

The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study

Effects of a synbiotic product on blood antioxidative activity in subjects colonized with Helicobacter pylori

Effect of Probiotic Supplementation on Intestinal Permeability in Overweight and Obesity: A Systematic Review of Randomized Controlled Trials and Animal Studies

Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial

On probiotic integration in the management of inflammation and the maintenance of the intestinal epithelial barrier’s integrity

Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury

The INHABIT (synergIstic effect of aNtHocyAnin and proBIoTics in) Inflammatory Bowel Disease trial: a study protocol for a double-blind, randomised, controlled, multi-arm trial

Protective Effect and Mechanism of Aspirin Eugenol Ester on Lipopolysaccharide-Induced Intestinal Barrier Injury

Acute gastric mucosal injury during continuous or interrupted aspirin ingestion in humans

Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial

Tu1228 Effect of Phosphatidylcholine (PC)-Aspirin on Small Bowel Mucosal Injury